Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections (LBP003)

Inclusion Criteria:

• Both genders eligible for study.
• Female participants must use a contraceptive method.
• Tuberculin skin test between 1 and 15mm
• Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.
• Subjects registered in a social security system or with health insurance cover
• First group: Healthy subjects aged from 18 to 75 years with 2 subgroups: 18-40 and 60-75 year old subjects
• Second group: Patients with kidney transplants of longer than 6 months on immunosuppressive treatment

Exclusion Criteria:

• Pregnant or lactating women.
• Previous allergic reaction to tuberculin skin test
• Active skin disease on testing zone
• Patients with a clinically significant disease (chronic, recurrent or active)
• Local or systemic medication which interacts with the outcome measures.
• Patients deprived of their civic rights, in custody, or under the care of a tutorial, judiciary or administrative body.
• Patients relevant of a protection measure
• Patients in a critical medical situation
• Patients with a personal situation evaluated by the investigator as unable to give an optimal participation in the study, or where it could constitute a risk for the patient
• Linguistic barrier or psychological profile disabling the patient from signing the consent form
• Patient still in an exclusion period following participation in another clinical trial
• Patients having earned more than 4500€ in indemnities following participation in clinical trials during the last 12 months, including this study

For group 1 only:

• Systemic corticotherapy or immunosuppressive treatment within the 2 weeks before first visit or within 2 weeks before the third visit or the biopsies.
• Systemic non anti-inflammatory drugs the week before the first visit or within 1 week before the third visit or the biopsies